Leithner Katharina, Stacher Elvira, Wurm Robert, Ploner Ferdinand, Quehenberger Franz, Wohlkoenig Christoph, Bálint Zoltán, Polachova Jana, Olschewski Andrea, Samonigg Hellmut, Popper Helmut H, Olschewski Horst
Department of Pulmonology, University Clinic of Internal Medicine, Lung Cell Laboratory, Medical University of Graz, Auenbruggerplatz 20, Graz A-8036, Austria.
Lung Cancer. 2009 Jul;65(1):98-104. doi: 10.1016/j.lungcan.2008.10.015. Epub 2008 Dec 9.
Death receptor 4 (DR4) and death receptor 5 (DR5) are tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) receptors that activate apoptosis via the extrinsic apoptosis pathway. DcR1 and DcR2 are decoy receptors for TRAIL that act antagonistically. Intracellular trafficking of TRAIL receptors has been described, but the role of the subcellular localization of TRAIL receptors in non-small cell lung cancer (NSCLC) progression is unclear.
Expression and intracellular localization of pro-apoptotic and decoy TRAIL receptors were analyzed by immunohistochemistry in 50 samples of advanced or recurrent NSCLC. Using confocal microscopy, localization of TRAIL receptors was studied in NSCLC cell lines.
Cytoplasmic staining for all four TRAIL receptors was observed in the majority of samples. Nuclear staining was infrequent in the case of DR4 (12%) and DcR2 (8%), while DR5 and DcR1 were localized in the nucleus in 27% and 60% of samples. When overall survival was analyzed, cytoplasmic staining for DR5 in tumor cells (P=0.025) and nuclear staining for DR5 in tumor cells (P=0.007) were significant prognostic factors in univariate, as well as in multivariate analysis including clinicopathologic factors (P=0.026 and 0.021, respectively). In A549, NCI-H358, and A427 NSCLC cells all four TRAIL receptors were found to be mainly located perinuclearly, but also in the nucleus.
The study for the first time shows that TRAIL receptors are found in different intracellular compartments including the nucleus in NSCLC cells and that both nuclear and cytoplasmic DR5 might predict improved survival in patients with advanced NSCLC.
死亡受体4(DR4)和死亡受体5(DR5)是肿瘤坏死因子相关凋亡诱导配体(Apo2L/TRAIL)受体,可通过外源性凋亡途径激活凋亡。DcR1和DcR2是TRAIL的诱饵受体,起拮抗作用。已有关于TRAIL受体细胞内运输的描述,但TRAIL受体亚细胞定位在非小细胞肺癌(NSCLC)进展中的作用尚不清楚。
通过免疫组织化学分析50例晚期或复发性NSCLC样本中促凋亡和诱饵TRAIL受体的表达及细胞内定位。使用共聚焦显微镜研究NSCLC细胞系中TRAIL受体的定位。
在大多数样本中观察到所有四种TRAIL受体的细胞质染色。DR4(12%)和DcR2(8%)的细胞核染色较少见,而DR5和DcR1分别在27%和60%的样本中定位于细胞核。在分析总生存期时,肿瘤细胞中DR5的细胞质染色(P=0.025)和肿瘤细胞中DR5的细胞核染色(P=0.007)在单变量分析中是显著的预后因素,在包括临床病理因素的多变量分析中也是如此(分别为P=0.026和0.021)。在A549、NCI-H358和A427 NSCLC细胞中,发现所有四种TRAIL受体主要位于核周,但也位于细胞核中。
该研究首次表明,在NSCLC细胞中,TRAIL受体存在于包括细胞核在内的不同细胞内区室,并且细胞核和细胞质中的DR5都可能预示晚期NSCLC患者的生存期改善。